Investing

Investment analysis, share recommendations, and market insights.

Premium

Will these “forgiven” stocks justify investor support?

Over the next two weeks we will get the earnings show and tell from a number of companies that have had shockers over the past year or so but recently they have been ‘forgiven’ or at least trusted to perform better than expected. Given the fact that many such as Xero, WiseTech, CSL and others have picked up a get-out-of jail card of late, these companies will need to deliver something positive, or at least not give any new bad news.

Peter Switzer · August 17, 2026
Premium

Is Telstra back in the buy zone?

I have been a long-time fan of Telstra (TLS), not because it is a great company – because it is not – but because it is the dominant player providing services that none of us can go without. Further, as an investor, it is a super defensive stock which has reliable earnings, those earnings have been steadily increasing and it pays a good, almost fully franked dividend, which has also been increasing.

Paul Rickard · August 17, 2026
Premium

Regenerative medicine: two attractive buys in a fascinating niche

It is a very esoteric niche on the ASX, but regenerative medicine is a fascinating area. ASX-listed companies PolyNovo, AVITA Medical and AROA Biosurgery all focus on regenerative medicine and soft-tissue repair, targeting severe burns, trauma and complex wounds, using active biological or structural reconstruction.

James Dunn · August 17, 2026
Premium

Questions of the Week (13 August 2026)

Is Perth shipbuilder Austal (ASB) being taken over? Why is Suncorp (SUN) paying a fully franked special dividend of 10c per share? What do the brokers think of location sharing app company Life360 which got smashed after its result on Tuesday? Does CBA offer a dividend re-investment plan, and if so, how do I tell them I want to participate?

Paul Rickard · August 13, 2026
Premium

“HOT” stock: BHP

Michael Gable, Managing Director of Fairmont Equities, says mining giant BHP (BHP) is breaking out to new highs and providing a fresh buying opportunity ahead of its full year results on 18 August.

Maureen Jordan · August 13, 2026
Premium

Resmed feels like good value

The healthcare sector has had a tough 12 months. But there are signs the worst may be over, and Resmed’s strong quarterly result is one […]

Paul Rickard · August 10, 2026

You don't have credit card details available. You will be redirected to update payment method page. Click OK to continue.